| Nov-21-18 08:00AM |
Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals Fundamental Analysis, Key Performance Indications |
GlobeNewswire |
| Nov-01-18 10:09AM |
XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update |
PR Newswire |
| Jul-24-18 09:09AM |
XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update |
PR Newswire |
| May-29-18 05:37PM |
XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update |
PR Newswire |
| Dec-13-17 07:30AM |
Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells |
ACCESSWIRE |
| Dec-06-17 12:08PM |
XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements |
PR Newswire |
| Nov-27-17 10:30AM |
XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results |
PR Newswire |
| Oct-23-17 11:23AM |
XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements |
PR Newswire |
| Oct-06-17 07:30AM |
Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy |
ACCESSWIRE |
| Oct-05-17 07:50AM |
Earnings Review and Free Research Report: DelMar Missed Earnings Expectations |
ACCESSWIRE |
| Sep-26-17 09:23AM |
XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| Sep-12-17 09:00AM |
XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome |
PR Newswire |
| Jul-11-17 07:00AM |
Featured Company News Inotek Pharma Announces Top-line Results of Phase-2 FDC Trial of Trabodenoson and Offers Corporate Update |
Accesswire |
| Jun-15-17 09:00AM |
XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| Apr-27-17 09:50AM |
XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors |
PR Newswire |
| Apr-05-17 09:10AM |
XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome |
PR Newswire |
| Apr-05-17 09:10AM |
XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögrens Syndrome |
|
| Mar-30-17 08:55AM |
XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| Mar-22-17 09:22AM |
XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors |
PR Newswire |
| Mar-07-17 12:40PM |
XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors |
PR Newswire |
| Mar-01-17 08:30AM |
XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement |
PR Newswire |
| Feb-17-17 08:00AM |
XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering |
PR Newswire |
| Feb-13-17 09:08AM |
XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome |
PR Newswire |
| Jan-25-17 08:30AM |
XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program |
PR Newswire |
| Jan-05-17 08:30AM |
XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome |
PR Newswire |
| Dec-19-16 08:00AM |
XTL Biopharmaceuticals to Present at Biotech Showcase |
PR Newswire |
| Dec-06-16 08:30AM |
XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| Nov-09-16 01:25PM |
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements |
PR Newswire |
| Sep-27-16 08:30AM |
XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| Sep-07-16 08:32AM |
XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1 |
PR Newswire |
| Sep-06-16 08:00AM |
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016 |
PR Newswire |
| Aug-11-16 09:00AM |
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1 |
PR Newswire |
| Jun-02-16 09:11AM |
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected 4 Billion Dollar Market |
|
| Jun-01-16 08:30AM |
XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| May-16-16 11:45AM |
XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016 |
PR Newswire |
| Apr-07-16 01:04PM |
XTL BIOPHARMACEUTICALS LTD Financials |
|
| Mar-31-16 09:45AM |
XTL Biopharmaceuticals Reports 2015 Financial Results & Provides Clinical and Operational Update |
PR Newswire |
| Mar-21-16 08:30AM |
XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of Lupus |
PR Newswire |
| Mar-09-16 08:29AM |
Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals |
PR Newswire |
| Mar-02-16 09:00AM |
XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent in Hungary for Lupus Drug hCDR1 |
PR Newswire |
| Feb-22-16 09:02AM |
XTL Biopharmaceuticals Receives European Medicines Agency's SME Status |
PR Newswire |
| Feb-10-16 08:30AM |
XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes |
PR Newswire |
| Jan-27-16 08:30AM |
XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America |
PR Newswire |
| Jan-25-16 08:30AM |
XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for Lupus Drug hCDR1 |
PR Newswire |
| Jan-13-16 08:30AM |
XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol® |
PR Newswire |
| Jan-11-16 08:30AM |
XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus |
PR Newswire |
| Dec-01-15 08:30AM |
XTL Biopharmaceuticals Reports Third Quarter 2015 Results and Confirms Intention to Start Lupus Trial In 2016 |
PR Newswire |
| Nov-09-15 08:30AM |
Cellect Biomed Announces Key Leadership Changes |
GlobeNewswire |
| Oct-28-15 09:00AM |
Dr. Murray Urowitz, of the University of Toronto University Health Network, Provides Overview of an Analysis of Data from a Phase II Clinical Study of hCDR1 (Edratide) for the Treatment of Lupus |
PR Newswire |
| Oct-26-15 09:15AM |
XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015 |
PR Newswire |
| Oct-13-15 08:45AM |
XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset |
PR Newswire |
| Sep-17-15 11:40AM |
XTL Biopharmaceuticals Ltd. Earnings Q2, 2015 |
|
| Sep-03-15 09:00AM |
XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC |
PR Newswire |
| Sep-01-15 09:00AM |
XTL Biopharmaceuticals Reports Second Quarter 2015 Results |
PR Newswire |
| Aug-26-15 09:00AM |
XTL Announces Publication of Results of Phase 2 Study on hCDR1 (Edratide) in Patients with Active Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine |
PR Newswire |
| Jun-01-15 08:00AM |
XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets |
PR Newswire |
| May-11-15 10:50AM |
XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference |
PR Newswire |
| May-09-15 09:45AM |
4 Speculative Biotechs With Huge Analyst Targets |
24/7 Wall St. |
| May-08-15 09:35AM |
XTL Biopharmaceuticals Aims To Tame Lupus, HC Wainwright Initiates At Buy |
|
| May-08-15 07:43AM |
Coverage initiated on XTL Biopharma by H.C. Wainwright |
|
| Apr-28-15 07:45AM |
XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014 |
PR Newswire |
| Mar-31-15 09:30AM |
XTL Biopharmaceuticals Announces Pricing of $4.0 Million Registered Direct Offering |
PR Newswire |
| Feb-17-15 08:30AM |
Biotech Investor Alex Rabinovich Increases Stake in XTL Biopharmaceuticals |
PR Newswire |
| Dec-30-14 12:23PM |
XTL Biopharmaceuticals Annual General Meeting of Shareholders Appoints Two New Members to the Board of Directors |
PR Newswire |
| Dec-08-14 08:30AM |
XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets |
PR Newswire |
| Dec-01-14 08:00AM |
XTL Biopharmaceuticals Provides Financial and Operational Update For the Third Quarter of 2014 |
PR Newswire |
| Sep-02-14 12:09PM |
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014 |
PR Newswire |
| Jul-22-14 02:54PM |
XTL Hopes To Begin Major Lupus Trial Next Year |
Seeking Alpha |
| Jul-16-14 09:18AM |
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity |
PR Newswire |
| Jun-12-14 08:00AM |
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements |
PR Newswire |
| Jun-02-14 09:00AM |
XTL Biopharmaceuticals Reports Financial and Operational Results for the First Quarter of 2014 |
PR Newswire |
| May-19-14 08:00AM |
XTL Biopharmaceuticals Further Strengthens Team for Phase II Lupus Trial with Two Additional Experts |
PR Newswire |
| Apr-02-14 04:41PM |
XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013 |
PR Newswire |
| Mar-25-14 08:00AM |
XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial |
PR Newswire |
| Jan-08-14 08:00AM |
XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus |
PR Newswire |